Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro (Q37358267)

19 August 2017

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro (English)

1 reference

19 August 2017

1 reference

Löwik C

1 reference

19 August 2017

van der Pluijm G

1 reference

19 August 2017

Vloedgraven H

1 reference

19 August 2017

van Beek E

1 reference

19 August 2017

van der Wee-Pals L

1 reference

19 August 2017

Papapoulos S

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

Journal of Clinical Investigation

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

698-705

1 reference

Resorption of bone by isolated rabbit osteoclasts

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Breast tumor cell lines from pleural effusions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

The clinical course of bone metastases from breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Rationale for the use of bisphosphonates in bone metastases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Mechanisms of osteolytic bone destruction

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bone metastases in breast cancer, prostate cancer and myeloma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Osteolytic bone metastasis in breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bone destruction in cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Mechanisms involved in the metastasis of cancer to bone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption

2 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment

5 November 2018

1 reference

12 December 2020

Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins

1 reference

12 December 2020

Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group

1 reference

12 December 2020

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

1 reference

12 December 2020

Antiresorptive dose-response relationships across three generations of bisphosphonates

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin

1 reference

12 December 2020

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

12 December 2020

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

12 December 2020

Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP

1 reference

12 December 2020

Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation

1 reference

12 December 2020

Development of skeletal metastases

1 reference

12 December 2020

Direct resorption of bone by human breast cancer cells in vitro

1 reference

12 December 2020

Mechanisms of lytic and blastic metastatic disease of bone

1 reference

12 December 2020

Mechanisms of bone destruction in the development of skeletal metastases

1 reference

12 December 2020

Identifiers

DOI

10.1172/JCI118841

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

8698861

1 reference